Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)

被引:23
|
作者
Xu, Yanyan [1 ,2 ]
Egido, Estefania [1 ,3 ,4 ]
Li-Blatter, Xiaochun [1 ]
Mueller, Rita [1 ]
Merino, Gracia [3 ,4 ]
Berneche, Simon [1 ,2 ]
Seelig, Anna [1 ]
机构
[1] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland
[2] Swiss Inst Bioinformat, CH-4056 Basel, Switzerland
[3] Univ Leon, INDEGSAL, E-24071 Leon, Spain
[4] Univ Leon, Fac Vet, Dept Biomed Sci Physiol, E-24071 Leon, Spain
基金
瑞士国家科学基金会;
关键词
BRAIN-BARRIER PERMEATION; MULTIDRUG-RESISTANCE; ATPASE ACTIVITY; DRUG TRANSPORT; SUBSTRATE RECOGNITION; STRUCTURAL BASIS; PLASMA-MEMBRANE; LIVING CELLS; SITES; ACTIVATION;
D O I
10.1021/acs.biochem.5b00649
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ATP binding cassette (ABC) transporters ABCG2 and ABCB1 perform ATP hydrolysis-dependent efflux of structurally highly diverse compounds, collectively called allocrites. Whereas much is known about allocrite-ABCB1 interactions, the chemical nature and strength of ABCG2-allocrite interactions have not yet been assessed. We quantified and characterized interactions of allocrite with ABCG2 and ABCB1 using a set of 39 diverse compounds. We also investigated potential allocrite binding sites based on available transporter structures and structural models. We demonstrate that ABCG2 binds its allocrites from the lipid membrane, despite their hydrophilicity. Hence, binding of allocrite to both transporters is a two-step process, starting with a lipid water partitioning step, driven mainly by hydrophobic interactions, followed by a transporter binding step in the lipid membrane. We show that binding of allocrite to both transporters increases with the number of hydrogen bond acceptors in allocrites. Scrutinizing the transporter translocation pathways revealed ample hydrogen bond donors for allocrite binding. Importantly, the hydrogen bond donor strength is, on average, higher in ABCG2 than in ABCB1, which explains the higher measured affinity of allocrite for ABCG2. pi-pi stacking and pi-cation interactions play additional roles in binding of allocrite to ABCG2 and ABCB1. With this analysis, we demonstrate that these membrane-mediated weak electrostatic interactions between transporters and allocrites allow for transporter promiscuity toward allocrites. The different sensitivities of the transporters to allocrites' charge and amphiphilicity provide transporter specificity. In addition, we show that the different hydrogen bond donor strengths in the two transporters allow for affinity tuning.
引用
收藏
页码:6195 / 6206
页数:12
相关论文
共 50 条
  • [41] Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
    Durmus, Selvi
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2012, 9 (11) : 3236 - 3245
  • [42] Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood-Brain Barrier
    Poller, Birk
    Wagenaar, Els
    Tang, Seng Chuan
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2011, 8 (02) : 571 - 582
  • [43] Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1
    Wu, Chung-Pu
    Hsiao, Sung-Han
    Sim, Hong-May
    Luo, Shi-Yu
    Tuo, Wei-Cherng
    Cheng, Hsing-Wen
    Li, Yan-Qing
    Huang, Yang-Hui
    Ambudkar, Suresh V.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (07) : 904 - 913
  • [44] The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)
    Kannan, Pavitra
    Telu, Sanjay
    Shukla, Suneet
    Ambudkar, Suresh V.
    Pike, Victor W.
    Halldin, Christer
    Gottesman, Michael M.
    Innis, Robert B.
    Hall, Matthew D.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (02): : 82 - 89
  • [45] Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier
    Bihorel, Sebastien
    Camenisch, Gian
    Lemaire, Michel
    Scherrmann, Jean-Michel
    JOURNAL OF NEUROCHEMISTRY, 2007, 102 (06) : 1749 - 1757
  • [46] Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin
    Pornngarm Limtrakul
    Wanida Chearwae
    Suneet Shukla
    Chada Phisalphong
    Suresh V. Ambudkar
    Molecular and Cellular Biochemistry, 2007, 296 : 85 - 95
  • [47] Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin
    Limtrakul, Pornngarm
    Chearwae, Wanida
    Shukla, Suneet
    Phisalphong, Chada
    Ambudkar, Suresh V.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2007, 296 (1-2) : 85 - 95
  • [48] The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
    Natarajan, Karthika
    Bhullar, Jasjeet
    Shukla, Suneet
    Burcu, Mehmet
    Chen, Zhe-Sheng
    Ambudkar, Suresh V.
    Baer, Maria R.
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (04) : 514 - 524
  • [49] Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer
    Nimisha
    Saluja, Sundeep S.
    Sharma, Abhay K.
    Nekarakanti, Phani K.
    Apurva, Arun
    Kumar, Arun
    Ahmad, Ejaj
    Husain, Syed A.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (05)
  • [50] Genomics and the mechanism of P-glycoprotein (ABCB1)
    Zuben E. Sauna
    In-Wha Kim
    Suresh V. Ambudkar
    Journal of Bioenergetics and Biomembranes, 2007, 39 : 481 - 487